3ZNB
| METALLO-BETA-LACTAMASE (ZN, HG-BOUND FORM) | Descriptor: | MERCURY (II) ION, METALLO-BETA-LACTAMASE, SODIUM ION, ... | Authors: | Concha, N.O, Herzberg, O. | Deposit date: | 1997-10-15 | Release date: | 1998-01-28 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Crystal structures of the cadmium- and mercury-substituted metallo-beta-lactamase from Bacteroides fragilis. Protein Sci., 6, 1997
|
|
2ZNB
| METALLO-BETA-LACTAMASE (CADMIUM-BOUND FORM) | Descriptor: | CADMIUM ION, METALLO-BETA-LACTAMASE, SODIUM ION | Authors: | Concha, N.O, Herzberg, O. | Deposit date: | 1997-10-14 | Release date: | 1998-01-28 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (2.15 Å) | Cite: | Crystal structures of the cadmium- and mercury-substituted metallo-beta-lactamase from Bacteroides fragilis. Protein Sci., 6, 1997
|
|
7T0O
| |
5DE1
| Crystal structure of human IDH1 in complex with GSK321A | Descriptor: | (7R)-1-(4-fluorobenzyl)-N-{3-[(1S)-1-hydroxyethyl]phenyl}-7-methyl-5-(1H-pyrrol-2-ylcarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide, Isocitrate dehydrogenase [NADP] cytoplasmic, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | Authors: | Concha, N.O, Smallwood, A, Qi, H. | Deposit date: | 2015-08-25 | Release date: | 2015-10-07 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat.Chem.Biol., 11, 2015
|
|
8SYC
| Crystal structure of PDE3B in complex with GSK4394835A | Descriptor: | MAGNESIUM ION, [3-[(4,7-dimethoxyquinolin-2-yl)carbonylamino]-5-[methyl-(phenylmethyl)carbamoyl]phenyl]-oxidanyl-oxidanylidene-boron, cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B | Authors: | Concha, N.O, Nolte, R. | Deposit date: | 2023-05-25 | Release date: | 2024-02-07 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded Library. J.Med.Chem., 67, 2024
|
|
6NT2
| type 1 PRMT in complex with the inhibitor GSK3368715 | Descriptor: | 2,3-DIHYDROXY-1,4-DITHIOBUTANE, GLYCEROL, N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine, ... | Authors: | Concha, N.O. | Deposit date: | 2019-01-28 | Release date: | 2019-07-10 | Last modified: | 2019-07-24 | Method: | X-RAY DIFFRACTION (2.48 Å) | Cite: | Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell, 36, 2019
|
|
6DXL
| Linked amidobenzimidazole STING agonist | Descriptor: | 1,1'-(butane-1,4-diyl)bis{2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-1H-benzimidazole-5-carboxamide}, CALCIUM ION, Stimulator of interferon protein | Authors: | Concha, N.O. | Deposit date: | 2018-06-29 | Release date: | 2018-11-07 | Last modified: | 2024-03-13 | Method: | X-RAY DIFFRACTION (2.45 Å) | Cite: | Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 564, 2018
|
|
6DXG
| amidobenzimidazole (ABZI) STING agonists | Descriptor: | 2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-1-[(2R)-2-hydroxy-2-phenylethyl]-1H-benzimidazole-5-carboxamide, CALCIUM ION, Stimulator of interferon protein | Authors: | Concha, N.O. | Deposit date: | 2018-06-28 | Release date: | 2018-11-07 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.905 Å) | Cite: | Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 564, 2018
|
|
2RAN
| RAT ANNEXIN V CRYSTAL STRUCTURE: CA2+-INDUCED CONFORMATIONAL CHANGES | Descriptor: | ANNEXIN V, CALCIUM ION, SULFATE ION | Authors: | Concha, N.O, Head, J.F, Kaetzel, M.A, Dedman, J.R, Seaton, B.A. | Deposit date: | 1994-09-01 | Release date: | 1994-11-30 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (1.89 Å) | Cite: | Rat annexin V crystal structure: Ca(2+)-induced conformational changes. Science, 261, 1993
|
|
3HHK
| HCV NS5b polymerase complex with a substituted benzothiadizine | Descriptor: | 2-({(3R)-3-[(3S)-1-(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinolin-3-yl]-1,1-dioxido-3,4-dihydro-2H-1,2,4-benzothiadiazin-7-yl}oxy)acetamide, HCV NS5 polymerase | Authors: | Concha, N.O, Singh, O. | Deposit date: | 2009-05-15 | Release date: | 2009-09-08 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. Bioorg.Med.Chem.Lett., 19, 2009
|
|
5KH4
| |
5KH2
| |
1ZNB
| METALLO-BETA-LACTAMASE | Descriptor: | METALLO-BETA-LACTAMASE, SODIUM ION, ZINC ION | Authors: | Concha, N.O, Herzberg, O. | Deposit date: | 1996-06-06 | Release date: | 1997-01-11 | Last modified: | 2024-02-14 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure, 4, 1996
|
|
5KH5
| |
2FVC
| Crystal structure of NS5B BK strain (delta 24) in complex with a 3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinone | Descriptor: | 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one, polyprotein | Authors: | Concha, N.O, Wonacott, A, Singh, O. | Deposit date: | 2006-01-30 | Release date: | 2007-01-16 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J.Med.Chem., 49, 2006
|
|
8UIA
| |
8UHO
| Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A | Descriptor: | 3C-like proteinase nsp5, N-[(benzyloxy)carbonyl]-4-fluoro-L-phenylalanyl-N-[(2S,3Z)-1-[(2S)-oxolan-2-yl]-3-(2-oxooxolan-3-ylidene)propan-2-yl]-L-leucinamide | Authors: | Concha, N.O, Williams, S.P. | Deposit date: | 2023-10-09 | Release date: | 2024-03-13 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement. Bioorg.Med.Chem., 100, 2024
|
|
8UIF
| Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A | Descriptor: | 3C-like proteinase nsp5, N-[(benzyloxy)carbonyl]-4-fluoro-L-phenylalanyl-N-{(2R)-1-[(2S)-oxolan-2-yl]-3-[(3S)-2-oxooxolan-3-yl]propan-2-yl}-L-leucinamide | Authors: | Concha, N.O, Williams, S.P. | Deposit date: | 2023-10-10 | Release date: | 2024-02-14 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement. Bioorg.Med.Chem., 100, 2024
|
|
4L04
| |
4L06
| |
4L03
| |
4KZO
| |
5VPM
| |
5VRP
| |
5V8V
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Renin, methyl [(4S)-4-(3'-ethyl-6-fluoro[1,1'-biphenyl]-2-yl)-4-hydroxy-4-{(3R)-1-[4-(methylamino)butanoyl]piperidin-3-yl}butyl]carbamate | Authors: | Concha, N, Zhao, B. | Deposit date: | 2017-03-22 | Release date: | 2017-10-18 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition. Bioorg. Med. Chem. Lett., 27, 2017
|
|